Clinical Trials Logo
  1. Home
  2. Melanoma
  3. NCT06237881

A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors

Melanoma Clinical Trial

Official title:
A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors

Clinical Trial Summary

To learn if KSQ-001EX is safe to give to participants with advanced forms of solid tumors.

Clinical Trial Description

Phase I Primary Objectives • To evaluate the safety and tolerability of KSQ-001EX in adult participants with advanced solid tumors (melanoma, HNSCC, NSCLC) Phase I Primary Endpoint • Incidence of dose-limiting toxicities (DLTs) Phase I Secondary Objectives - Determine expansion dose - Assess the safety and tolerability of KSQ-001EX in participants with advanced solid tumors (melanoma, HNSCC, NSCLC) - Evaluate preliminary antitumor activity of KSQ-001EX in participants with advanced solid tumors - Evaluate the feasibility of the manufacturing process. Phase I Secondary Endpoints - Incidence and severity of treatment-emergent adverse events (TEAEs) and change from Baseline in laboratory results - Objective response rate (ORR), duration of response (DOR), time to response (TTR) as assessed by the Investigator, per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 - Manufacturing success rate Phase 2 Primary Objectives • To assess the anti-tumor activity of KSQ-001EX in patients with advanced malignant solid tumors Phase 2 Primary Endpoint • ORR per RECIST v1.1 Phase 2 Secondary Objectives - Assess the safety and tolerability of KSQ-001EX in patients with advanced solid tumors (melanoma, HNSCC, NSCLC) - Evaluate anti-tumor activity of KSQ-001EX in patients with advanced malignant solid tumors - Evaluate overall survival (OS) - Evaluate the feasibility of the manufacturing process Phase 2 Secondary Endpoints - Incidence and severity of TEAEs and change from Baseline in laboratory results - Complete response rate (CRR), DOR, TTR, progression-free survival (PFS) per RECIST v1.1 - OS - Manufacturing success rate Phase 1/2 Exploratory Objectives - Determine persistence of KSQ-001EX - Assess changes in immune and pharmacodynamic markers following KSQ-001EX infusion - Assess correlations of KSQ-001EX biomarkers and KSQ-001EX DP characteristics with safety, clinical activity, and KSQ-001EX persistence Phase 1/2 Exploratory Endpoints - KSQ-001EX levels in blood and tumor tissue - Change from Baseline in soluble immune factors, lymphocytes and immune markers - KSQ-001EX pharmacodynamic markers, KSQ-001EX DP release criteria, and KSQ-001EX persistence ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06237881
Study type Interventional
Source M.D. Anderson Cancer Center
Contact Rodabe N Amaria, MD
Phone (713) 792-2921
Email rnamaria@mdanderson.org
Status Recruiting
Phase Phase 1/Phase 2
Start date January 31, 2024
Completion date January 1, 2029
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Completed NCT03979872 - Risk Information and Skin-cancer Education for Undergraduate Prevention N/A
Recruiting NCT04986748 - Using QPOP to Predict Treatment for Sarcomas and Melanomas
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Recruiting NCT05707286 - Pilot Study to Determine Pro-Inflammatory Cytokine Kinetics During Immune Checkpoint Inhibitor Therapy
Active, not recruiting NCT05470283 - Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma Phase 1
Recruiting NCT05077137 - A Feasibility Study Utilizing Immune Recall to Increase Response to Checkpoint Therapy Phase 1
Active, not recruiting NCT02721459 - XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma Phase 1
Active, not recruiting NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Recruiting NCT05839912 - Excision of Lymph Node Trial (EXCILYNT) (Mel69) N/A
Recruiting NCT04971499 - A Study of Dapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced Melanoma Phase 1/Phase 2
Recruiting NCT05060432 - Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT05263453 - HL-085+Vemurafenib to Treat Advanced Melanoma Patients With BRAF V600E/K Mutation Phase 2
Completed NCT03348891 - TNF in Melanoma Patients Treated With Immunotherapy N/A
Terminated NCT03399448 - NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells) Phase 1
Completed NCT03171064 - Exercise as a Supportive Measure for Patients Undergoing Checkpoint-inhibitor Treatment Phase 2
Not yet recruiting NCT05539118 - Interferon-α1b Combined With Toripalimab and Anlotinib Hydrochloride in Advanced Unresectable Melanoma Phase 1/Phase 2
Recruiting NCT05171374 - pRospective Evaluation of Clinical Outcomes in Patients With metAsTatIс melanOma Treated With dabrafeNib and trAmetinib in reaL practicE
Withdrawn NCT02854488 - Yervoy Pregnancy Surveillance Study
Completed NCT00297895 - Multicenter Selective Lymphadenectomy Trial II (MSLT-II) N/A